Telacebec

Synonym(s): Q203

Class: Imidazopyridine amide

Details of activity:	Active against Mycobacterium tuberculosis; inhibits mycobacterial cytochrome bc1 complex
Description:	Synthetic compound; shows a synergistic effect with PBTZ169 (Phase 2 anti-tuberculosis drug derived from BTZ-043)
Year first mentioned:	2013
Highest developmental phase:	Phase 2 (NCT06481163)
Development status:	Active (as of 2025)

Chemical structure(s):
Canonical SMILES:	CCC1=C(C(=O)NCC2=CC=C(C=C2)N3CCC(CC3)C4=CC=C(C=C4)OC(F)(F)F)N5C=C(C=CC5=N1)Cl
Isomeric SMILES:	CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)OC(F)(F)F
InChI:	InChI=1S/C29H28ClF3N4O2/c1-2-25-27(37-18-22(30)7-12-26(37)35-25)28(38)34-17-19-3-8-23(9-4-19)36-15-13-21(14-16-36)20-5-10-24(11-6-20)39-29(31,32)33/h3-12,18,21H,2,13-17H2,1H3,(H,34,38)
InChI Key:	OJICYBSWSZGRFB-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/68234908

External links:
Guide to Pharmacology:	telacebec
Main Source:	https://journals.asm.org/doi/10.1128/aac.00448-22
Citation:	https://www.nature.com/articles/nm.3262